
AstraZeneca buys in vivo cell therapy specialists EsoBiotec
AstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion. The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers. ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T… Read More















